Silihan lan utang jangka dawa perusahaan: Athira (ATHA)

Athira Pharma, Inc. (ATHA) minimizes capital expenditures by outsourcing compound synthesis and testing to external contractors. Stable revenue is currently absent, as the company's success is directly tied to the results of medical research on brain cell regeneration. The current metric stands at 0.00, and patient retention depends on FDA approval. This chart illustrates the company's share price action.

Long-term debt reflects the aggregate of credit obligations with maturities exceeding one year, allowing for an assessment of the issuer's financial stability and borrowing strategy. By analyzing the trajectory of the corporation's long-term loans and borrowings, an investor can determine the volume of external financing required by Athira Pharma, Inc. (ATHA) to cover the costs of phosgonimetone clinical trials and the development of Alzheimer's disease therapies.